JP2005145821A - Tablet preparation - Google Patents

Tablet preparation Download PDF

Info

Publication number
JP2005145821A
JP2005145821A JP2003381050A JP2003381050A JP2005145821A JP 2005145821 A JP2005145821 A JP 2005145821A JP 2003381050 A JP2003381050 A JP 2003381050A JP 2003381050 A JP2003381050 A JP 2003381050A JP 2005145821 A JP2005145821 A JP 2005145821A
Authority
JP
Japan
Prior art keywords
surface portion
tablet
tableting
convex
portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003381050A
Other languages
Japanese (ja)
Inventor
Kiminari Iriyama
公成 入山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2003381050A priority Critical patent/JP2005145821A/en
Publication of JP2005145821A publication Critical patent/JP2005145821A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide a tablet preparation that controls a tableting trouble and has excellent mechanical strengths. <P>SOLUTION: This tablet preparation is equipped with a surface part 2, a bottom part 3 and a side peripheral surface part 4 connected to the surface part 2 and the bottom part 3. At least one of the surface part 2 and the bottom art 3 is dispersedly equipped with at least two or more projected parts 22 and 32 projected from base surface parts 20 and 30. The projected part 22 has a curved surface 223 and an inclined surface 224 and a cross-sectional shape from the base surface parts 20 and 30 changes. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

本発明は、打錠障害、特にキャッピングの発生を抑えることができる打錠製剤及びその製造型に関する。   The present invention relates to a tableting preparation capable of suppressing the occurrence of tableting troubles, particularly capping, and a production type thereof.

製造時に空気を抱き込ませて空隙率を高め、内服後に素早く解けて効能が発現するようにした打錠製剤として、例えば、口腔内速崩錠等が知られている。このような打錠製剤は、製造時に打錠圧力が低く抑えられ、空隙率が高められているため、キャッピングやラミネーションなどの打錠障害が生じやすい。このため、包装や輸送の際に加わる衝撃によって容易に割れや欠けが生じる問題があった。   For example, intraoral quick-disintegrating tablets are known as tableting preparations that are entrapped with air at the time of manufacture to increase the porosity, and are quickly released after internal use so that their effects are expressed. Such a tableting formulation has a low tableting pressure at the time of production and a high porosity, so that tableting troubles such as capping and lamination are likely to occur. For this reason, there has been a problem that cracks and chipping easily occur due to an impact applied during packaging and transportation.

一方、生体付着性の錠剤に関する従来技術として、例えば、下記特許文献1に記載の技術が提案されている。この技術は、生体付着性錠剤の表面に一定の断面(空間)を有する直線状若しくは曲線状の凹部を、同心円状又は平行に一定間隔(表面積に対して釣り合いのとれた比率を持つ数及び間隔)で設け、錠剤化と生体への付着性を改善したものである。   On the other hand, as a conventional technique related to a bioadhesive tablet, for example, a technique described in Patent Document 1 below has been proposed. In this technique, linear or curved concave portions having a constant cross section (space) are formed on the surface of a bioadhesive tablet, concentrically or in parallel at constant intervals (numbers and intervals having a proportion proportional to the surface area). ) To improve tableting and adherence to living bodies.

しかしながら、この技術は、錠剤の表面に深さや断面が一定の凹部が同心円状又は平行に一定間隔で設けられているため、打錠時に加わる圧縮力によって粒子が層状に並びやすくなり、打錠障害の一つであるラッピングやラミネーションを引き起こしやすくなっていた。このため、この技術をそのまま適用しても、上記課題を根本的に解決し得る手段となり得なかった。   However, this technology has concentric or parallel recesses with a constant depth and cross section on the surface of the tablet, and the particles are easily arranged in layers due to the compressive force applied during tableting. It was easy to cause wrapping and lamination which is one of the above. For this reason, even if this technique is applied as it is, it cannot be a means for fundamentally solving the above-mentioned problems.

特許第3024756号公報Japanese Patent No. 3024756

本発明は、上述の問題に鑑みてなされたものであり、その目的は、打錠障害の発生が抑えられ、機械的強度に優れた打錠製剤を提供することにある。   This invention is made | formed in view of the above-mentioned problem, The objective is to provide the tableting formulation which generation | occurrence | production of the tableting trouble was suppressed and was excellent in mechanical strength.

本発明者らは、表面に特定の形状を付与した錠剤が、その製造時における打錠障害の発生を抑え得ることを知見し、本発明を完成するに至った。   The present inventors have found that a tablet having a specific shape on its surface can suppress the occurrence of tableting troubles during its production, and have completed the present invention.

本発明は、上記知見に基づきなされたものであり、上面部、底面部並びに該上面部及び該底面部に連なる側周面部を備えており、前記上面部又は前記底面部の少なくとも一方に、それらの基面部から突出した凸部及び/若しくは窪んだ凹部が、少なくとも二以上分散して設けられている打錠製剤であって、前記凸部又は前記凹部は、その表面に曲面若しくは傾斜面を有し、且つ前記基面部からの断面形状が変化している打錠製剤を提供するものである。   The present invention has been made on the basis of the above knowledge, and includes an upper surface portion, a bottom surface portion, and a side peripheral surface portion connected to the upper surface portion and the bottom surface portion, and at least one of the upper surface portion or the bottom surface portion is provided with them. A tableting preparation in which at least two or more convex portions and / or concave concave portions protruding from the base surface portion are provided in a dispersed manner, and the convex portion or the concave portion has a curved surface or an inclined surface on the surface thereof. And the tableting formulation in which the cross-sectional shape from the said base-surface part is changing is provided.

また、本発明は、上記本発明の打錠製剤を製造するための製造型であって、一組の成形型からなり、前記上面部及び前記底面部並びに前記側周面部に対応した成形面をそれぞれ有している製造型を提供するものである。   Further, the present invention is a production mold for producing the tableting preparation of the present invention, comprising a set of molds, and molding surfaces corresponding to the upper surface portion, the bottom surface portion, and the side peripheral surface portion. Each of the manufacturing molds is provided.

本発明の打錠製剤は、製造時の打錠障害の発生が抑えられ、機械的強度に優れている。従って、包装時、輸送時、使用時等に一時的な衝撃を受けて割れや欠けが発生することを抑えることができる。
また、本発明の製造型によれば、上記効果を奏する本発明の打錠製剤を好適に製造することができる。
The tableting preparation of the present invention is excellent in mechanical strength because occurrence of tableting troubles during production is suppressed. Therefore, it is possible to suppress the occurrence of cracks and chips due to a temporary impact during packaging, transportation, use, and the like.
Moreover, according to the manufacturing type of this invention, the tableting formulation of this invention which show | plays the said effect can be manufactured suitably.

以下、本発明を、その好ましい実施形態に基づいて、図面を参照しながら説明する。   Hereinafter, the present invention will be described based on preferred embodiments with reference to the drawings.

図1は、本発明の打錠製剤(以下、単に錠剤ともいう。)を口腔内服薬に適用した一実施形態を示すものである。図1において符号1は錠剤を示している。   FIG. 1 shows an embodiment in which the tableting preparation of the present invention (hereinafter also simply referred to as a tablet) is applied to an oral medicine. In FIG. 1, reference numeral 1 denotes a tablet.

図1に示すように、錠剤1は、上面部2、底面部3並びに上面部2及び底面部3に連なる側周面部4を備えている。上面部2及び底面部3は、平面視して円形状に設けられている。上面部2及び底面部3は、円形状以外の形状、例えば、楕円状、長円状、多角形状とすることもできる。多角形の場合には、その角にいわゆる面取りを施して所望の曲率半径の曲面状に設けることが好ましい。本発明の錠剤には、いわゆる造粒のみによって粒状に成形された剤は含まない。   As shown in FIG. 1, the tablet 1 includes an upper surface portion 2, a bottom surface portion 3, and a side peripheral surface portion 4 that continues to the upper surface portion 2 and the bottom surface portion 3. The top surface portion 2 and the bottom surface portion 3 are provided in a circular shape in plan view. The upper surface portion 2 and the bottom surface portion 3 may be formed in a shape other than a circular shape, for example, an elliptical shape, an oval shape, or a polygonal shape. In the case of a polygon, it is preferable to provide a so-called chamfered corner to provide a curved surface with a desired radius of curvature. The tablet of the present invention does not contain an agent formed into granules by so-called granulation alone.

上面部2又は底面部3を平面視したときの面積(側周面部4における断面積)は、支障なく服用できる大きさとする点、所望の効能が得られるような服用量とする点、包装しやすい大きさとする点、輸送時の錠剤の破損を抑制する点等を考慮すると、4〜360mm2、特に10〜115mm2が好ましい。 The area when the top surface 2 or the bottom surface portion 3 is viewed in plan (the cross-sectional area of the side peripheral surface portion 4) is a size that can be taken without any hindrance, a dose that provides a desired effect, and packaging. In consideration of the easy size, the suppression of tablet breakage during transportation, and the like, 4 to 360 mm 2 , particularly 10 to 115 mm 2 is preferable.

また、上面部2及び底面部3を平面視したときの寸法(側周面部4における断面の最小寸法及び最大寸法)は、支障なく服用できる大きさとする点、所望の効能が得られるような服用量とする点、溶解時間、崩壊時間を遅延させない大きさとする点、打錠時の圧縮性とその排出時の作動性が良好な点、包装時や輸送時の錠剤の破損を防御する大きさとする点、錠剤の形状により転がり難くさせる点を考慮すると、最小寸法が2〜20mm、特に3〜10mmが好ましく、最大寸法が3〜30mm、特に5〜15mmが好ましい。ここで、該最小寸法とは、上面部又は底面部を平面視したときの形状が楕円状、長円状、多角形状の場合に、その短径をいう。該最大寸法は、本実施形態のように、上面部2又は底面部3を平面視したときの形状が円形状の場合にはその直径となる。   In addition, the dimensions of the top surface 2 and the bottom surface 3 when viewed in plan (minimum and maximum dimensions of the cross section of the side peripheral surface 4) should be such that they can be taken without any problem, and can be used to obtain a desired effect. Point that does not delay the amount, dissolution time, disintegration time, good compressibility at the time of tableting and operability at the time of discharge, and size that prevents breakage of the tablet at the time of packaging or transportation In consideration of the point of making it difficult to roll depending on the shape of the tablet, the minimum dimension is preferably 2 to 20 mm, particularly preferably 3 to 10 mm, and the maximum dimension is preferably 3 to 30 mm, particularly 5 to 15 mm. Here, the minimum dimension means a short diameter when the shape of the top surface or the bottom surface when viewed in plan is an ellipse, an ellipse, or a polygon. The maximum dimension is the diameter when the shape of the upper surface portion 2 or the bottom surface portion 3 when viewed in plan is circular as in this embodiment.

錠剤1は、基面部20、30が両面部とも同じ凸面状(曲面状)に設けられている。基面部は、平面や凹面状に設けることもできるし、少なくとも一面が曲面状に設けられていれば、各形状を組み合わせて設けることもできる。本実施形態のような凸面状とする場合や、凹面状とする場合には、打錠良好な形状とする点、転がりにくい形状とする点、つまみやすい形状とする点、組み合わせ凸部(又は凹部)により打錠圧縮時に圧縮粒子が層状に配列するのを妨げる形状とする点を考慮すると、基面部(凸面状の場合及び凹面状の場合を含む)の曲率半径は6.5mm以上、特に10mm以上とすることが好ましい。本実施形態では、基面部20、30は、その外周縁部に所定幅の平坦部21、31が設けられているが、これらの平坦部は設けなくてもよい。   In the tablet 1, the base surface portions 20 and 30 are provided in the same convex shape (curved surface shape) on both surface portions. The base surface portion can be provided in a flat shape or a concave shape, or can be provided in combination with each other as long as at least one surface is provided in a curved shape. In the case of a convex shape as in this embodiment, or in the case of a concave shape, a point that makes tableting good, a point that makes it difficult to roll, a point that makes it easy to pick, a combination convex part (or a concave part) ), The radius of curvature of the base surface portion (including the convex surface and the concave surface) is 6.5 mm or more, particularly 10 mm. The above is preferable. In the present embodiment, the base surface portions 20 and 30 are provided with flat portions 21 and 31 having a predetermined width on the outer peripheral edge portion thereof, but these flat portions may not be provided.

錠剤1は、上面部2及び底面部3に、それらの基面部20、30から突出する凸部22、32が二以上(6個)分散して設けられているが、本発明においては、凸部(又は凹部)は、上面部又は底面部の何れか一方にのみ設けることもできる。凸部(又は凹部)は、上面部及び底面部に偏在することなくほぼ均一に分散するように設けられていることが好ましい。上面部及び底面部の両面に凸部(又は凹部)を設ける場合には、当該凸部(又は凹部)は、裏表同じ位置に配することもできるし、対称(回転対称、鏡面対称、線対称など)の位置に配することもできるし、本発明の効果を損なわない範囲において、幾何学的に無関係な分散状態に配することもできる。   The tablet 1 is provided with two or more (six) convex portions 22 and 32 protruding from the base surface portions 20 and 30 on the upper surface portion 2 and the bottom surface portion 3. The portion (or the recess) can be provided only on either the top surface portion or the bottom surface portion. The convex portions (or concave portions) are preferably provided so as to be distributed substantially uniformly without being unevenly distributed on the upper surface portion and the bottom surface portion. In the case where convex portions (or concave portions) are provided on both the upper surface portion and the bottom surface portion, the convex portions (or concave portions) can be arranged at the same position on the front and back sides, and symmetrical (rotational symmetry, mirror symmetry, line symmetry). Etc.), and in a range that does not impair the effects of the present invention, it can also be distributed in a geometrically irrelevant state.

図2に示すように、凸部22、32(凹部を設ける場合は凹部)は、その表面に曲面223及び傾斜面224を有しており、且つ基面部20、30からの断面形状(凹部の場合には、凹部の作る開口断面の形状をいう。)が変化している。凸部の表面を斯かる形態とすることで、打錠時に圧縮力が高い部分を局所的に配することができ、打錠障害を誘発するような圧縮粒子の層状に並ぶことを効果的に抑えることができる。この場合、曲面223の曲率半径は、0.5〜30mm、特に5〜10mmとすることが好ましい。傾斜面224の傾斜角度(基面部が湾曲している場合には凸部(又は凹部)の外縁における該基面部の接線に対する角度)θは、1〜89度、特に5〜75度とすることが好ましい。また、前記凸部22、32(凹部を設ける場合は凹部)における、基面部20、30に連なる周縁部は、基面部20、30に対して所定の角度で傾斜しているか又は湾曲していることが好ましい。斯かる断面形状や上述の分散の観点から、錠剤の表面への文字や記号等の刻印は、本発明の錠剤における凸部及び凹部には、含まない。ただし、本発明の錠剤には、その効果を損なわない範囲において、その表面にこれらの刻印を有していてもよい。   As shown in FIG. 2, the convex portions 22 and 32 (concave portions when concave portions are provided) have a curved surface 223 and an inclined surface 224 on the surface, and a cross-sectional shape from the base surface portions 20 and 30 (recessed portions). In this case, the shape of the opening cross section formed by the recess is changed). By adopting such a form on the surface of the convex portion, it is possible to locally arrange a portion having a high compressive force at the time of tableting, and to effectively arrange in a layered form of compressed particles that induce a tableting failure. Can be suppressed. In this case, the radius of curvature of the curved surface 223 is preferably 0.5 to 30 mm, particularly 5 to 10 mm. The inclination angle of the inclined surface 224 (when the base surface portion is curved, the angle with respect to the tangent to the base surface portion at the outer edge of the convex portion (or concave portion)) θ is 1 to 89 degrees, particularly 5 to 75 degrees. Is preferred. Moreover, the peripheral edge part which continues to the base-surface parts 20 and 30 in the said convex parts 22 and 32 (it is a recessed part when providing a recessed part) is inclined at a predetermined angle with respect to the base-surface parts 20 and 30, or is curving. It is preferable. From the viewpoint of such a cross-sectional shape and the above-mentioned dispersion, inscriptions such as letters and symbols on the surface of the tablet are not included in the convex portion and the concave portion in the tablet of the present invention. However, the tablet of the present invention may have these marks on the surface thereof as long as the effect is not impaired.

本発明の打錠製剤において、前記凸部(又は前記凹部)は、前記基面部からの断面形状が変化するように設けられており、該凸部(又は該凹部)は、該凸部(又は該凹部)を特定の鉛直平面で断面視したときに、該基面部からの高さ(又は該基面部からの凹部の深さ)が変化するように、すなわち、該断面において該基面部からの高さ(又は該基面部からの凹部の深さ)が一定にならないように設けられている。該変化は連続的であることが好ましい。ここで、前記基面部からの高さ(又は該基面部からの凹部の深さ)とは、該基面部の延在面(例えば、図2では破線で図示。)からの高さ(又は該基面部の延在面からの凹部の鉛直深さ)をいう。   In the tableting preparation of the present invention, the convex portion (or the concave portion) is provided so that a cross-sectional shape from the base surface portion changes, and the convex portion (or the concave portion) is the convex portion (or the concave portion). When the cross-sectional view of the concave portion is taken along a specific vertical plane, the height from the base surface portion (or the depth of the concave portion from the base surface portion) changes, that is, from the base surface portion in the cross-section. The height (or the depth of the recess from the base surface portion) is provided so as not to be constant. The change is preferably continuous. Here, the height from the base surface portion (or the depth of the recess from the base surface portion) is the height from the extended surface of the base surface portion (for example, shown by a broken line in FIG. 2) (or the The vertical depth of the concave portion from the extending surface of the base surface portion).

図1に示すように、本実施形態の錠剤1では、凸部22、32は、平面視した場合には、上面部2及底面部3において花柄を表しており、平面視して円形状の一つの花芯220、320と、末広がりで花芯の外側に等角度に配された5枚の花びら221、321とからなっている。凸部(及び凹部)の数及び形状は、後述する面積や面積率、間隔、高さ(深さ)、基面部の接線に対する立ち上がり角度に応じて適宜設定することができる。花柄以外の形態としては、基本図形及びこれで構成された葉、動物、魚類、貝類、果物、乗り物、天体物、文具などの雑貨、人体パーツ、食べ物等が挙げられる。隣接する凸部どうしの間隔は、圧縮された粒子に層状配列を生じさせない間隔とする点、圧縮打錠の打錠杵の成形可能な間隔とする点、滑りにくく、転がりにくい接点を設ける点を考慮すると、0.2〜25mm、特に0.3〜2mmとすることが好ましい。   As shown in FIG. 1, in the tablet 1 of the present embodiment, the convex portions 22 and 32 represent a floral pattern on the upper surface portion 2 and the bottom surface portion 3 when viewed in plan, and are circular in plan view. , And five petals 221 and 321 arranged at equal angles on the outer side of the flower core. The number and shape of the convex portions (and concave portions) can be appropriately set according to the area, area ratio, interval, height (depth), and rising angle with respect to the tangent line of the base surface portion, which will be described later. Examples of forms other than the floral pattern include basic figures and leaves, animals, fish, shellfish, fruits, vehicles, astronomical objects, stationery and other miscellaneous items, human body parts, food, and the like. The interval between adjacent convex portions is a point that does not cause a layered arrangement in the compressed particles, a point that can be formed into a compression punch for compression tableting, and a point that is difficult to slip and does not roll easily. Considering it, it is preferable to set it as 0.2-25 mm, especially 0.3-2 mm.

凸部22、32(凹部を設けた場合には凹部)の個々の面積は、圧縮打錠した錠剤の粒子配列が均一な層状配列を形成させないで錠剤中の圧縮応力に差を生じさせる面積を形成する点を考慮すると、0.5〜321mm2、特に、0.7〜80mm2が好ましい。該面積が斯かる範囲内であると、圧縮された錠剤中の粒子が層状に並ばず、圧力の高いポイントが点在するために、キャッピングを生じ難くする。また凸部(又は凹部)があることで、錠剤の接地エリアが狭くなり、結果、錠剤の厚みが増し、つまみやすくなる。本実施形態の錠剤1の場合は、0.5〜23mm2、特に3〜15mm2が好ましい。ここで、該面積は、個々の面積形状に応じ、映像拡大処理して得られる図面、又はノギスで計測した寸法に基づいて形状を製図して得られた図面等から計算によって求められる値である。 The individual areas of the protrusions 22 and 32 (recesses in the case where recesses are provided) are the areas that cause a difference in the compression stress in the tablets without forming a uniform layered array of the tablet tablet tablets. Considering the formation point, 0.5 to 321 mm 2 , particularly 0.7 to 80 mm 2 is preferable. When the area is within such a range, the particles in the compressed tablet are not arranged in layers, and high pressure points are scattered, so that capping is hardly caused. Further, the presence of the convex portion (or concave portion) narrows the tablet contact area, resulting in an increase in tablet thickness and ease of pinching. In the case of the tablet 1 of this embodiment, 0.5-23 mm < 2 >, especially 3-15 mm < 2 > are preferable. Here, the area is a value obtained by calculation from a drawing obtained by image enlargement processing or a drawing obtained by drawing a shape based on a dimension measured with a caliper according to each area shape. .

上面部2、底面部3の面積に対する、凸部22、32の個々の面積率(本実施形態の場合には花芯220、320及び花びら221、321の個々の面積率)は、1〜46%、特に6〜26%が好ましい。該面積率が斯かる範囲内であると、凸部(又は凹部)があることで、錠剤の上面部2又は底面部3の接地面が狭くなる結果、錠剤の厚みが増してつまみやすくなる。また、錠剤の上面部又は底面部の接地点と接触面との摩擦が生じて滑りにくくなる。本実施形態の錠剤1の場合は、該面積率は、1〜26%、特に、6〜12%が好ましい。ここで、該面積率は、凸部22、32の個々の面積を上面部2、底面部3それぞれの面積で除した百分率で表される値である。   The individual area ratios of the convex parts 22 and 32 with respect to the areas of the top surface part 2 and the bottom surface part 3 (in the case of this embodiment, the individual area ratios of the flower cores 220 and 320 and the petals 221 and 321) are 1 to 46. %, Particularly 6 to 26% is preferred. When the area ratio is within such a range, the presence of the convex portion (or the concave portion) narrows the ground contact surface of the upper surface portion 2 or the bottom surface portion 3 of the tablet. In addition, friction between the contact point and the ground contact point on the top surface or bottom surface of the tablet is difficult to slip. In the case of the tablet 1 of this embodiment, the area ratio is preferably 1 to 26%, particularly preferably 6 to 12%. Here, the area ratio is a value expressed as a percentage obtained by dividing the individual areas of the convex portions 22 and 32 by the respective areas of the top surface portion 2 and the bottom surface portion 3.

また、上面部2、底面部3のそれぞれの面積に対する、凸部22、32のそれぞれの合計の面積率は、2〜97%、特に38〜84%が好ましい。該面積率が斯かる範囲内であると、凸部(又は凹部)を設け易くなり、錠剤中に圧縮応力に差が生じた凸部(または凹部)が2点以上生じ、局在的に、圧力がかかるため、圧縮された粉粒体は、層状配列を乱すことになり、キャッピングを生じにくくさせる。本実施形態の錠剤1の場合は、50〜70%、特に52〜65%が好ましい。ここで、該面積率は、凸部22、32の合計の面積を上面部2、底面部3それぞれの面積で除した百分率で表される値である。   Further, the total area ratio of the convex portions 22 and 32 with respect to the areas of the top surface portion 2 and the bottom surface portion 3 is preferably 2 to 97%, particularly preferably 38 to 84%. When the area ratio is within such a range, it becomes easy to provide a convex portion (or a concave portion), two or more convex portions (or concave portions) in which a difference in compression stress occurs in the tablet, and locally, Since pressure is applied, the compressed granular material disturbs the layered arrangement and makes capping difficult to occur. In the case of the tablet 1 of this embodiment, 50 to 70%, particularly 52 to 65% is preferable. Here, the area ratio is a value expressed as a percentage obtained by dividing the total area of the convex portions 22 and 32 by the area of the top surface portion 2 and the bottom surface portion 3.

錠剤1の厚み(最大厚み)は、錠剤の崩壊時間が遅延しない点、厚みが増すことによる転がり易さが増す点を考慮すると、1.5〜12mm、特に2.5〜7.5mmとすることが好ましい。また、側周面部4の高さは、打錠杵同士が圧縮成形時に接触して損傷しない程度に間隔を開けなければならない点、基面部より突出した凸部(または凹部)によって生じる圧縮応力の影響を受けることで、圧縮粒子が層状に配列するのを防ぐのに十分な厚さにする点を考慮すると、0.5〜10mm、特に1〜5mmとすることが好ましい。   The thickness (maximum thickness) of the tablet 1 is 1.5 to 12 mm, particularly 2.5 to 7.5 mm in consideration of the fact that the disintegration time of the tablet is not delayed and the ease of rolling due to the increase in thickness. It is preferable. Further, the height of the side peripheral surface portion 4 is such that the tableting rivets must be spaced apart from each other at the time of compression molding so as not to be damaged, and the compressive stress generated by the convex portion (or concave portion) protruding from the base surface portion. In consideration of the influence, it is preferable to set the thickness to 0.5 to 10 mm, particularly 1 to 5 mm, considering that the thickness is sufficient to prevent the compressed particles from being arranged in layers.

本実施形態の錠剤1は、多孔性構造を有する口腔内服錠、特に口腔内速崩錠に有効である。ここで、多孔性構造とは、通常空隙率が5〜80%、特に好ましくは10〜50%であることを意味している。一般に多孔性構造を有すると速崩性が高まるが、一方でキャッピングの発生、硬度や対衝撃性の低下を生じやすい。本発明においては、速崩性の向上に加えて、打錠時の圧縮成形性、キャッピングの防止、硬度、対衝撃性の向上が図られる。ここで、空隙率とは、錠剤の構成成分や造粒された顆粒、圧縮された錠剤等の中に存在する空間の割合を示すもので、一般に口腔内速崩錠では多孔性構造を指標として表すのに利用されている。   The tablet 1 of this embodiment is effective for an oral cavity tablet having a porous structure, particularly an intraoral quick disintegrating tablet. Here, the porous structure usually means that the porosity is 5 to 80%, particularly preferably 10 to 50%. Generally, having a porous structure increases the rapid disintegration property, but tends to cause capping and a decrease in hardness and impact resistance. In the present invention, in addition to improving fast disintegrating property, compression moldability at the time of tableting, prevention of capping, hardness and impact resistance are improved. Here, the porosity indicates the proportion of the space present in the constituent components of the tablet, granulated granules, compressed tablets, etc. Generally, in the oral rapid disintegrating tablet, the porous structure is used as an index. Used to represent.

次に、錠剤1の製造方法について説明する。
図3(a)〜(f)は、錠剤1を製造するための製造型を示すものである。
Next, the manufacturing method of the tablet 1 is demonstrated.
3A to 3F show a production mold for producing the tablet 1.

製造型は、棒状の上杵12及び下杵13並びに筒状の臼14からなる一組の成形型からなる。上杵12は前記上面部2に対応した成形面120を有している。下杵13は前記底面部3に対応した成形面130を有している。臼14は、前記側周面部4に対応した成形面140を有している。   The production mold is composed of a set of molds composed of rod-shaped upper and lower rods 12 and 13 and a cylindrical die 14. The upper collar 12 has a molding surface 120 corresponding to the upper surface portion 2. The lower collar 13 has a molding surface 130 corresponding to the bottom surface portion 3. The mortar 14 has a molding surface 140 corresponding to the side peripheral surface portion 4.

上記製造型を構成する上杵12、下杵13及び臼14、は、金属、セラミックス等の従来からこの種の製造型に用いられる通常の材質により製造することができる。   The upper punch 12, the lower punch 13 and the mortar 14 constituting the manufacturing mold can be manufactured by a conventional material such as metal, ceramics and the like conventionally used for this type of manufacturing mold.

上記製造型を用いた錠剤の製造方法は、従来の固形製剤の製造方法と同様の手順で製造することができる。
例えば、上記製造型を、打錠機(図示せず)にセットし、図4(a)に示すように下杵13及び臼14をあらかじめ組み合わせておき、錠剤1の原料10となる所定の配合組成の打錠用顆粒を充填する。そして、図4(b)に示すように、上杵12を下杵13の上方からおろし、図4(c)に示すように上杵12及び下杵13間に原料を挟持して所定の圧力で打錠することで、所望の形態の錠剤を得る。
The manufacturing method of the tablet using the said manufacturing type can be manufactured in the procedure similar to the manufacturing method of the conventional solid formulation.
For example, the above-mentioned production mold is set in a tableting machine (not shown), and the lower punch 13 and the mortar 14 are combined in advance as shown in FIG. Fill the tableting granules of composition. Then, as shown in FIG. 4B, the upper rod 12 is lowered from above the lower rod 13, and the raw material is sandwiched between the upper rod 12 and the lower rod 13 as shown in FIG. To obtain tablets of the desired form.

打錠の際の押圧力(打錠圧)は、許容圧力範囲内において、錠剤厚、径、錠剤の硬度、崩壊時間等の錠剤の物理的性質に応じて適宜設定することができるが、錠剤の空隙性、成形性、硬度、崩壊等の錠剤の物理学的性質を考慮すると、1.96×105〜1.96×108Pa、特に2.94×105〜9.81×107Paとすることが好ましい。ここで、打錠の際の押圧力は、打錠機の圧力から打錠杵の単位面積あたり(打錠杵の粉粒体充填空間の軸方向の単位断面積あたり)の圧力を換算して求められる値である。 The pressing force (tablet pressure) at the time of tableting can be appropriately set in accordance with the physical properties of the tablet such as tablet thickness, diameter, tablet hardness, disintegration time, etc. within the allowable pressure range. When considering the physical properties of the tablet such as porosity, moldability, hardness and disintegration of 1.96 × 10 5 to 1.96 × 10 8 Pa, particularly 2.94 × 10 5 to 9.81 × 10. 7 Pa is preferable. Here, the pressing force at the time of tableting is calculated by converting the pressure per unit area of the tableting punch (per unit cross-sectional area in the axial direction of the powder filling space of the tableting punch) from the pressure of the tableting machine. This is the required value.

また、打錠の際には、圧縮した錠剤の上面部又は底面部の基面部より突出した凸部及び/若しくは窪んだ凹部によって圧力差が生じ、錠剤、特に上面部又は底面部に近い場所での圧縮粒子が層状に配列し難くなる点を考慮すると、上面部又は底面部の表面における最大圧縮応力と最小圧縮応力との差が15〜1800N/mm2、特に200〜800N/mm2となるように押圧力をかけることが好ましい。この場合、打錠機本体への機械的負荷や、打錠杵の破損、圧力による錠剤の空隙率低下に伴う崩壊時間延長の点から、前記最大圧縮応力は150〜2000N/mm2、特に250〜1000N/mm2とすることが好ましい。また、前記最小圧縮応力は、20〜500N/mm2、特に70〜200N/mm2とすることが好ましい。ここで、前記最大圧縮応力、前記最小圧縮応力及びこれらの差は、例えば、錠剤の上面部又は底面部の基面部形状とそこから突出若しくは窪んだ凹凸をCAD等の立体図面に再現し、錠剤の直径(長円状、楕円状である場合には短径)、表面積を計算する。さらに錠剤の単位面積あたりに換算した圧力値を出し、そこから有限要素法により、図面上に圧力分布を導き、この錠剤上面部又は底面部での凹凸部の分布差を計算することにより求めることができる。 Further, when tableting, a pressure difference is generated by a convex part and / or a concave part that protrudes from the base part of the upper surface or the bottom part of the compressed tablet, and the tablet, particularly in a place close to the upper part or the bottom part. In consideration of the point that it becomes difficult to arrange the compressed particles in a layered manner, the difference between the maximum compressive stress and the minimum compressive stress on the surface of the top surface portion or the bottom surface portion is 15 to 1800 N / mm 2 , particularly 200 to 800 N / mm 2. It is preferable to apply a pressing force. In this case, the maximum compressive stress is 150 to 2000 N / mm 2 , particularly 250 in view of mechanical load on the tablet press body, breakage of the tablet punch, and extension of the disintegration time due to reduction in the porosity of the tablet due to pressure. ˜1000 N / mm 2 is preferable. The minimum compressive stress is preferably 20 to 500 N / mm 2 , particularly 70 to 200 N / mm 2 . Here, the maximum compressive stress, the minimum compressive stress, and the difference between them, for example, reproduce the shape of the base surface portion of the upper surface or the bottom surface of the tablet and the unevenness protruding or recessed therefrom in a three-dimensional drawing such as CAD, The diameter (the ellipse or the ellipse is the short diameter) and the surface area are calculated. Furthermore, the pressure value converted per unit area of the tablet is obtained, and from this, the pressure distribution is derived on the drawing by the finite element method, and it is obtained by calculating the distribution difference of the uneven portion at the top or bottom of the tablet. Can do.

また、錠剤中の圧縮粒子の配列を確認する方法として、錠剤の上面部と底面部の一又は二方向から圧力をかけて二分割し、その断面に錠剤不溶性の着色液をスプレーし、目視又は拡大処理した画像より、その粒子配列の状態を確認して求めることができる。または錠剤の打錠杵を再現し、二色以上の着色粉粒体を圧縮打錠前に臼内でそれぞれ均一な層状に積層させ、圧縮後、上記方法と同様に錠剤を二分割し、目視又は拡大処理した画像より、その粒子配列の状態を確認して求めることができる。   Further, as a method for confirming the arrangement of the compressed particles in the tablet, the tablet is divided into two parts by applying pressure from one or two directions of the upper surface and the bottom surface of the tablet, and sprayed with a tablet-insoluble coloring liquid on the cross section, and visually or The state of the particle arrangement can be confirmed and obtained from the enlarged image. Alternatively, the tablet punches of the tablet are reproduced, and two or more colored powder particles are laminated in a uniform layer in the mortar before compression tableting, and after compression, the tablet is divided into two parts in the same manner as above, and visually or The state of the particle arrangement can be confirmed and obtained from the enlarged image.

打錠は、打錠製剤の構成成分に悪影響を与えない温度、例えば、常温(20〜30℃)で行うことが好ましい。   Tableting is preferably performed at a temperature that does not adversely affect the components of the tableting preparation, for example, at room temperature (20 to 30 ° C.).

打錠機には、単発打錠機、ロータリー式打錠機、積層打錠機、ロータリー式有核打錠機等を用いることができる。   As the tableting machine, a single tableting machine, a rotary tableting machine, a laminated tableting machine, a rotary cored tableting machine or the like can be used.

本実施形態の錠剤1には、従来から口腔内服薬に用いられている粒径の通常の粉粒体(粉体又は顆粒)からなる組成物を特に制限なく用いることができる。該粉粒体は、その粒径が5〜500μmで該粒径の粉粒体を95vol%以上含んでいることが好ましく、粒径が75〜300μmで該粒径の粒径を50vol%以上含んでいることがより好ましい。かかる粒径の範囲の粉粒体を用いることで、本発明の効果がより一層奏される。該粒径は、市販の粒度分布測定器(例えば、レーザー式粒度分布測定器等)で測定することができる。   For the tablet 1 of the present embodiment, a composition composed of a normal granular material (powder or granule) having a particle diameter conventionally used for oral medicine can be used without particular limitation. It is preferable that the granular material has a particle size of 5 to 500 μm and contains 95 vol% or more of the granular material, and a particle size of 75 to 300 μm and contains 50 vol% or more of the particle size. More preferably. The effect of the present invention is further exhibited by using a granular material having such a particle size. The particle size can be measured with a commercially available particle size distribution measuring device (for example, a laser type particle size distribution measuring device).

打錠終了後、図4(d)に示すように、上杵12を上方に引き上げ、さらに下杵13を上方に引き上げて臼14内から錠剤1を取り出して製造を終了する。   After tableting is finished, as shown in FIG. 4 (d), the upper punch 12 is pulled upward, the lower punch 13 is further lifted upward, and the tablet 1 is taken out from the die 14 to complete the manufacture.

本実施形態の錠剤1は、上述のように、上面部2、底面部3に曲面及び傾斜面を有するとともに基面部20、30より突出した所定の断面を有する凸部22(又は窪んだ凹部)を2以上分散して有しているので、錠剤1の上面部2又は底面部3において、圧力の高い点が局在し、圧縮粒子が均一な層状に配列し難くなり、層状の割れを抑えることができる。従って、キャッピング等の打錠障害の発生が抑えられ、機械的強度に優れたものとなる。特に、打錠時に局所的に圧縮力が加わって硬度が高められているため、耐衝撃性に優れている。このため、包装時や輸送時等に一時的に衝撃が加わった場合にも割れや欠け等の破損が生じにくい。また、表面に凹凸部があるので、摘みやすく、放置したときには転がり難く、滑りにくい。特に、上面部2又は底面部3の面積に対する、凸部22、32の個々の面積率及び凸22、32それぞれの合計の面積率がそれぞれ所定範囲にあるので、上記効果が一層奏される。   As described above, the tablet 1 according to the present embodiment has a curved surface and an inclined surface on the upper surface portion 2 and the bottom surface portion 3 and a convex portion 22 (or a depressed concave portion) having a predetermined cross section protruding from the base surface portions 20 and 30. 2 or more are dispersed in the upper surface portion 2 or the bottom surface portion 3 of the tablet 1 so that high pressure points are localized, making it difficult for the compressed particles to be arranged in a uniform layer shape and suppressing layered cracks. be able to. Therefore, the occurrence of tableting troubles such as capping can be suppressed, and the mechanical strength is excellent. In particular, since the hardness is increased by applying a compressive force locally at the time of tableting, it is excellent in impact resistance. For this reason, even when a temporary impact is applied at the time of packaging or transportation, breakage such as cracking or chipping hardly occurs. In addition, since there are uneven portions on the surface, it is easy to pick, and it is difficult to roll and slip when left unattended. In particular, since the individual area ratios of the protrusions 22 and 32 and the total area ratio of the protrusions 22 and 32 with respect to the area of the upper surface portion 2 or the bottom surface portion 3 are within a predetermined range, the above effect is further exhibited.

本発明は前記実施形態に制限されるものではなく、本発明の趣旨を逸脱しない範囲において、適宜変更することができる。   The present invention is not limited to the above-described embodiment, and can be changed as appropriate without departing from the spirit of the present invention.

本発明の錠剤には、必要に応じ、従来から内服薬に用いられている糖衣等の通常の被覆層を、通常の方法で設けることもできる。このような被覆層で被覆した場合にも、その断面観察によって、錠剤の寸法形状等は容易に求めることができる。   If necessary, the tablet of the present invention may be provided with a usual coating layer such as sugar coating conventionally used for internal use by a usual method. Even when coated with such a coating layer, the size and shape of the tablet can be easily determined by observing the cross section.

本発明の打錠製剤は、口腔内速崩錠のほか、一般的な素錠、チュアブル錠、多層錠、有核錠、これらをコア錠としたフィルム錠、糖衣錠等の錠剤にも適用することができる。   The tableting preparation of the present invention can be applied to tablets such as film tablets, sugar-coated tablets, etc., which are ordinary core tablets, chewable tablets, multilayer tablets, dry-coated tablets, core tablets, in addition to intraoral rapidly disintegrating tablets Can do.

以下、実施例により本発明を更に具体的に説明する。なお、本発明は本実施例に何等制限されるものではない。   Hereinafter, the present invention will be described more specifically with reference to examples. In addition, this invention is not restrict | limited to a present Example at all.

下記配合組成の打錠用顆粒を用い、表1に示すような実施例及び比較例の製造条件で口腔内速崩錠を作製した。そして得られた錠剤の形態(錠厚及び質量を含む。)を調べるとともに、該錠剤の物性を下記のように評価した。それらの結果を表1に示した。   Intraoral rapidly disintegrating tablets were produced under the production conditions of Examples and Comparative Examples as shown in Table 1 using granules for tableting having the following composition. And while examining the form (including tablet thickness and mass) of the obtained tablet, the physical property of this tablet was evaluated as follows. The results are shown in Table 1.

〔打錠用顆粒〕
<配合組成>
結晶セルロース(旭化成製、アビセルPH101):5.0重量%
D−マンニトール(東和化成工業製、マンニットS):77.0重量%
乳糖(DMV社製、DMV22メッシュ):5.0重量%
クロスポピドン(ISP社製、ポリプラスドンXL−10):5重量%
カルメロースカルシウム(ニチリン化学工業製、ECG―505):5.0重量%
ステアリン酸マグネシウム(日本油脂製、日局ステアリン酸マグネシウム):3.0重量%
<粒径>
5〜517μm(堀場製作所製、レーザー式粒度分布測定器「LA−920」にて測定。)
[Tabletting granules]
<Composition composition>
Crystalline cellulose (Asahi Kasei, Avicel PH101): 5.0% by weight
D-mannitol (manufactured by Towa Kasei Kogyo Co., Ltd., Mannit S): 77.0% by weight
Lactose (DMV, DMV22 mesh): 5.0% by weight
Crospopidone (manufactured by ISP, polyplastidone XL-10): 5% by weight
Carmellose calcium (Nichirin Chemical Industries, ECG-505): 5.0% by weight
Magnesium stearate (manufactured by Nippon Oil & Fats, JP Magnesium Stearate): 3.0% by weight
<Particle size>
5 to 517 μm (measured with a laser particle size distribution measuring instrument “LA-920” manufactured by Horiba, Ltd.)

〔実施例1〕
図1に示す前記実施形態の錠剤1において、下記寸法形状に設定するとともに、上面部及び底面部の同じ位置に同じ凸部が配されるように、対応する前記図3の製造型を配し、表1に示す打錠圧で錠剤を作製した。打錠に際しては、下記打錠機を用いた。
<錠剤の形態>
花びらの数:5枚
花芯の面積:3.14mm2
花びら1枚の面積:4.63mm2
花(花芯及び全花びら=凸部)の面積:26.27mm2
錠剤の前記上面部、前記底面部それぞれの面積:50.27mm2
錠剤の前記上面部、前記底面部それぞれの面積に対する一つの花びらの面積率:9.21%
錠剤の前記上面部、前記底面部それぞれの面積に対する花の面積率:52.27%
曲面状の上面部及び底面部の基面部の曲率半径:12mm
<打錠機>
ロータリー式打錠機(菊水製作所製)
[Example 1]
In the tablet 1 of the embodiment shown in FIG. 1, the following dimensional shape is set, and the corresponding manufacturing mold of FIG. Tablets were produced at the tableting pressure shown in Table 1. For tableting, the following tableting machine was used.
<Tablet form>
Number of petals: 5 Area of flower core: 3.14 mm 2
Area of one petal: 4.63mm 2
Area of flower (flower core and all petals = convex part): 26.27 mm 2
Area of each of the upper surface portion and the bottom surface portion of the tablet: 50.27 mm 2
Area ratio of one petal with respect to the area of each of the upper surface portion and the bottom surface portion of the tablet: 9.21%
Flower area ratio with respect to the area of each of the upper surface portion and the bottom surface portion of the tablet: 52.27%
Curvature radius of curved top surface and bottom surface: 12mm
<Tablet press>
Rotary tableting machine (manufactured by Kikusui Seisakusho)

〔実施例2〕
上面部及び底面部の基面部を平坦面とした以外は、実施例1と同様にして錠剤を作製した。
[Example 2]
A tablet was produced in the same manner as in Example 1 except that the top surface and the base surface of the bottom surface were flat.

〔実施例3〕
底面部に凸部を設けず、曲率半径が12mmの曲面状の基面部のみとした以外は、実施例1と同様にして錠剤を作製した。
Example 3
A tablet was prepared in the same manner as in Example 1 except that no convex portion was provided on the bottom surface and only a curved base surface portion having a curvature radius of 12 mm was used.

〔実施例4〕
底面部に凸部を設けず、平坦面の基面部のみとした以外は、実施例1と同様にして錠剤を作製した。
Example 4
A tablet was produced in the same manner as in Example 1 except that the bottom surface portion was not provided with a convex portion and only a flat base surface portion was provided.

〔比較例〕
上面部及び底面部のいずれにも凸部を設けずに、上面部及び底面部のいずれも曲率半径が10mmの曲面状の基面部のみ形成した以外は、実施例1と同様にして錠剤を作製した。
[Comparative example]
A tablet is produced in the same manner as in Example 1 except that no convex portion is provided on either the top surface portion or the bottom surface portion, and that only the curved base surface portion having a curvature radius of 10 mm is formed on both the top surface portion and the bottom surface portion. did.

〔空隙率の評価〕
得られた錠剤について、実施例、比較例で用いた打錠用顆粒の真密度を求め、次式により計算し、空隙率を評価した。
空隙率=[{錠剤の体積−(錠剤の質量/打錠用顆粒の真密度)}/錠剤の体積]×100
真密度測定器:MICROMERTICS AccuPyc1330(島津製作所製)
[Evaluation of porosity]
About the obtained tablet, the true density of the granule for tableting used by the Example and the comparative example was calculated | required, it calculated by following Formula, and the porosity was evaluated.
Porosity = [{volume of tablet− (mass of tablet / true density of granule for tableting)} / volume of tablet] × 100
True density measuring instrument: MICROMERTICS AccuPyc1330 (manufactured by Shimadzu Corporation)

〔硬度の評価〕
得られた錠剤について、下記圧力試験器を用い、下記条件で、該錠剤を側周面で立てた状態で当該側周面部の上方から押圧子を当接させ、該錠剤の破壊強度及び破壊状態を調べた。試験は10回行い、それらの平均値を錠剤の硬度とした。
圧力試験器:Versa Tester(Mecmesin社製)
押圧子の移動速度:100mm/min
[Evaluation of hardness]
About the obtained tablet, using the following pressure tester, under the following conditions, with the tablet standing on the side peripheral surface, a presser is brought into contact from above the side peripheral surface portion, and the breaking strength and the breaking state of the tablet I investigated. The test was performed 10 times, and the average value thereof was taken as the hardness of the tablet.
Pressure tester: Versa Tester (made by Mecmesin)
Movement speed of the presser: 100mm / min

〔摩損度の評価〕
得られた錠剤について、100錠の質量を測定し、摩損度試験器にて回転速度25rpmで400回回転させた後の錠剤の質量の差を測定して、次式により摩損度を評価した。
摩損度={(試験前の100錠の質量−試験後の100錠の質量)/試験前の100錠の質量}×100
摩損度試験器:錠剤摩損度試験器、TFH−120(富山産業製)
[Evaluation of friability]
About the obtained tablet, the mass of 100 tablets was measured, the difference in the mass of the tablet after rotating 400 times at a rotational speed of 25 rpm with a friability tester was measured, and the friability was evaluated by the following formula.
Friction = {(mass of 100 tablets before test−mass of 100 tablets after test) / mass of 100 tablets before test} × 100
Abrasion tester: Tablet friability tester, TFH-120 (manufactured by Toyama Sangyo)

〔崩壊性の評価〕
得られた錠剤について、第14改正日本薬局方に記載されている崩壊試験法により、崩壊時間を測定した。試験は6回行い、それらの崩壊時間の平均値で崩壊性を評価した。
崩壊試験器:NT-1HM(富山産業製)
[Evaluation of disintegration]
About the obtained tablet, disintegration time was measured by the disintegration test method described in the 14th revision Japanese Pharmacopoeia. The test was performed 6 times, and the disintegration property was evaluated by the average value of the disintegration times.
Collapse tester: NT-1HM (Toyama Sangyo)

〔落下強度の評価〕
得られた錠剤(10錠)を高さ1.3mから直径5cmのボール紙製の筒の中を通してアクリル製の落下板に3回落下させたときの当該錠剤の状態を目視によって調べた。
(Evaluation of drop strength)
When the obtained tablets (10 tablets) were dropped three times onto a drop plate made of acrylic through a cardboard tube having a height of 1.3 m to a diameter of 5 cm, the state of the tablets was examined visually.

表1に示したように、実施例1〜4のように、所定の面積率で上面部又は底面部に凸部を形成した錠剤は、機械的強度(硬度及び落下強度)に優れていた。これに対し、比較例の錠剤は、機械的強度も低く、割れた状態もいわゆるキャッピングのように層状に破壊されていた。また、上面部が花柄の凸部、底面部が凸部のない曲面で構成された実施例3、4の錠剤を硬度測定すると、上面部に凸部を有する錠剤の方が中心部分で2分割に割れる率が高く、逆に底面部に凸部を有しない曲面部側では、層状に割れる率が高かった。一般に、多孔性構造を有する口腔内速崩錠等は、ラミネーションやキャッピングといった打錠障害が発生しやすいが、本発明により、打錠障害の一つであるラミネーションやキャッピング等の層状に割れる現象を効果的に抑制できることが判った。さらに、本発明の打錠製剤は、錠剤の上面部又は底面部に局面若しくは傾斜面を有するとともに基面部より突出した所定の断面を有する凸部(又は窪んだ凹部)を2以上分散して有しているので、錠剤の上面部又は底面部において、圧力の高い点が局在し、圧縮粒子が均一な層状に配列し難くなるので層状の割れを生じにくくしている。この局在的な高い圧縮力は、錠剤表面の硬度を高め、落下試験で示されたように対衝撃性を向上させ得ることが判った。   As shown in Table 1, as in Examples 1 to 4, tablets having protrusions on the top surface or bottom surface with a predetermined area ratio were excellent in mechanical strength (hardness and drop strength). On the other hand, the tablet of the comparative example had low mechanical strength, and the broken state was broken into layers like so-called capping. In addition, when the hardness of the tablets of Examples 3 and 4 in which the upper surface portion is configured with a flower-shaped convex portion and the bottom surface portion is configured with a curved surface without the convex portion, the tablet having the convex portion on the upper surface portion is 2 in the central portion. The rate of cracking was high, and conversely, the rate of cracking in a layered manner was high on the curved surface side having no convex portion on the bottom surface. Generally, intraoral quick-disintegrating tablets having a porous structure are prone to tableting troubles such as lamination and capping, but according to the present invention, a phenomenon that breaks into layers such as lamination and capping, which is one of tableting troubles. It was found that it can be effectively suppressed. Furthermore, the tableting preparation of the present invention has two or more dispersed convex portions (or depressed concave portions) having a predetermined cross section that protrudes from the base surface portion and has an aspect or inclined surface on the upper surface portion or the bottom surface portion of the tablet. Therefore, high pressure points are localized on the top surface or bottom surface of the tablet, and the compressed particles are difficult to be arranged in a uniform layer, so that layered cracks are less likely to occur. It has been found that this localized high compressive force can increase the hardness of the tablet surface and improve the impact resistance as shown in the drop test.

本発明の錠剤を口腔内速崩錠に適用した一実施形態を示すものであり、(a)は平面図、(b)はA−A断面図、(c)は底面図である。1 shows an embodiment in which the tablet of the present invention is applied to an intraoral rapidly disintegrating tablet, wherein (a) is a plan view, (b) is a cross-sectional view along AA, and (c) is a bottom view. 本発明の錠剤の要部の拡大図である。It is an enlarged view of the principal part of the tablet of this invention. 本発明の錠剤の製造型を模式的に示す図であり、(a)は上杵の正面図、(b)は上杵のB−B断面図、(c)は臼の正面図、(d)は臼の側断面図、(e)は下杵の正面図、(f)は下杵のC−C断面図である。It is a figure which shows the manufacturing type | mold of the tablet of this invention typically, (a) is a front view of an upper punch, (b) is BB sectional drawing of an upper punch, (c) is a front view of a die, (d ) Is a side cross-sectional view of the mortar, (e) is a front view of the lower punch, and (f) is a CC cross-sectional view of the lower punch. 本発明の錠剤の製造型を用いた錠剤の製造工程を模式的に示す図であり、(a)は原料を充填した状態を示す図、(b)は臼への上杵の挿入状態を示す図、(c)は打錠を行っている状態を示す図、(c)は脱型した状態を示す図である。It is a figure which shows typically the manufacturing process of the tablet using the tablet manufacturing type | mold of this invention, (a) is a figure which shows the state with which the raw material was filled, (b) shows the insertion state of the upper arm in the die (C) is a figure which shows the state which is performing tableting, (c) is a figure which shows the state which removed.

符号の説明Explanation of symbols

1 錠剤
2 上面部
20 基面部
21 平坦部
22 凸部
3 底面部
30 基面部
31 平坦部
32 凸部
4 側周面部
10 原料
12 上杵
13 下杵
14 臼

DESCRIPTION OF SYMBOLS 1 Tablet 2 Upper surface part 20 Base surface part 21 Flat part 22 Convex part 3 Bottom part 30 Base surface part 31 Flat part 32 Convex part 4 Side surface part 10 Raw material 12 Upper arm 13 Lower arm 14 Mill

Claims (5)

上面部、底面部並びに該上面部及び該底面部に連なる側周面部を備えており、前記上面部又は前記底面部の少なくとも一方に、それらの基面部から突出した凸部及び/若しくは窪んだ凹部が、少なくとも二以上分散して設けられている打錠製剤であって、
前記凸部又は前記凹部は、その表面に曲面若しくは傾斜面を有し、且つ前記基面部からの断面形状が変化している打錠製剤。
A top surface portion, a bottom surface portion, and a side peripheral surface portion connected to the top surface portion and the bottom surface portion are provided, and at least one of the top surface portion and the bottom surface portion protrudes from a base surface portion thereof and / or a recessed recess portion. Is a tableting formulation provided in a dispersed manner at least two,
The convex part or the concave part has a curved surface or an inclined surface on the surface thereof, and a tableting preparation in which a cross-sectional shape from the base surface part is changed.
前記上面部又は前記底面部の面積に対する、前記凸部若しくは前記凹部の個々の面積率及び該凸部若しくは該凹部の合計の面積率がそれぞれ2〜46%及び2〜97%である請求項1記載の打錠製剤。   2. The area ratio of each of the convex portions or the concave portions and the total area ratio of the convex portions or the concave portions with respect to the area of the upper surface portion or the bottom surface portion is 2 to 46% and 2 to 97%, respectively. The tableting formulation described. 前記基面部が少なくとも一方が曲面状に設けられており、その曲率半径が6.5mm以上である請求項1又は2記載の打錠製剤。   The tableting preparation according to claim 1 or 2, wherein at least one of the base surface portions is provided in a curved shape, and the radius of curvature thereof is 6.5 mm or more. 口腔内服薬に用いられ、空隙率が5〜80%である請求項1〜3の何れかに載の打錠製剤。   The tableting preparation according to any one of claims 1 to 3, which is used for oral administration and has a porosity of 5 to 80%. 請求項1記載の打錠製剤を製造するための製造型であって、一組の成形型からなり、前記上面部、前記底面部及び前記側周面部に対応した成形面を有している製造型。

A production mold for producing the tableting preparation according to claim 1, comprising a set of molds and having molding surfaces corresponding to the upper surface portion, the bottom surface portion and the side peripheral surface portion. Type.

JP2003381050A 2003-11-11 2003-11-11 Tablet preparation Pending JP2005145821A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003381050A JP2005145821A (en) 2003-11-11 2003-11-11 Tablet preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003381050A JP2005145821A (en) 2003-11-11 2003-11-11 Tablet preparation

Publications (1)

Publication Number Publication Date
JP2005145821A true JP2005145821A (en) 2005-06-09

Family

ID=34690547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003381050A Pending JP2005145821A (en) 2003-11-11 2003-11-11 Tablet preparation

Country Status (1)

Country Link
JP (1) JP2005145821A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255066A1 (en) * 2007-09-28 2010-10-07 Lintec Corporation Orally-administered agent
US20100278899A1 (en) * 2007-12-06 2010-11-04 Lintec Corporation Edible film
US20110027325A1 (en) * 2008-03-28 2011-02-03 Lintec Corporation Orally-administered agent
US20110182954A1 (en) * 2008-09-29 2011-07-28 Lintec Corporation Orally-administered agent
JP2018140973A (en) * 2017-02-28 2018-09-13 花王株式会社 Bath agent
CN109131198A (en) * 2018-10-29 2019-01-04 湖北航天化学技术研究所 A kind of gas generant for air cell tablet and its preparation process and gasifier system

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501847A (en) * 1980-12-05 1982-10-14
JPS5824515A (en) * 1981-07-20 1983-02-14 ワ−ナ−−ランバ−ト・コンパニ− Tablet and preparation
JPS6112620A (en) * 1984-06-22 1986-01-21 スミス・クライン・アンド・フレンチ・ラボラトリース・リミテッド Medicine bend unit
JPS61289027A (en) * 1985-06-04 1986-12-19 サンド・アクチエンゲゼルシヤフト Tablet
JPS62116688U (en) * 1986-01-14 1987-07-24
JPS62141027U (en) * 1986-02-24 1987-09-05
JPS6486835A (en) * 1987-09-29 1989-03-31 Remon Glass Food Kk Preparation of candy or tablet
JPH05186363A (en) * 1991-06-24 1993-07-27 American Cyanamid Co Transplanting composition containing biologically active protein, peptide or polypeptide
JPH08500599A (en) * 1992-09-01 1996-01-23 ベーリンガー マンハイム ゲーエムベーハー Stretched splittable tablets
JPH0853345A (en) * 1994-08-10 1996-02-27 Pfizer Pharmaceut Co Ltd Divisible tablet provided with film coating
JPH08277217A (en) * 1995-04-05 1996-10-22 Sumitomo Pharmaceut Co Ltd Splittable tablet
JPH10175850A (en) * 1996-12-12 1998-06-30 Dainippon Pharmaceut Co Ltd Deformed type division tablet
JPH11152221A (en) * 1997-07-30 1999-06-08 Jenapharm Gmbh Bioadhesive tablet and its production
WO1999051207A1 (en) * 1998-04-03 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Split tablet and press-through pack
JP2002028222A (en) * 2000-04-28 2002-01-29 Kyowa Hakko Kogyo Co Ltd Tablet dividing appliance, tablet and press-through pack
JP2002531225A (en) * 1998-12-04 2002-09-24 クノル アクチエンゲゼルシヤフト Dividable solid dosage form and method for producing the same

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501847A (en) * 1980-12-05 1982-10-14
JPS5824515A (en) * 1981-07-20 1983-02-14 ワ−ナ−−ランバ−ト・コンパニ− Tablet and preparation
JPS6112620A (en) * 1984-06-22 1986-01-21 スミス・クライン・アンド・フレンチ・ラボラトリース・リミテッド Medicine bend unit
JPS61289027A (en) * 1985-06-04 1986-12-19 サンド・アクチエンゲゼルシヤフト Tablet
JPS62116688U (en) * 1986-01-14 1987-07-24
JPS62141027U (en) * 1986-02-24 1987-09-05
JPS6486835A (en) * 1987-09-29 1989-03-31 Remon Glass Food Kk Preparation of candy or tablet
JPH05186363A (en) * 1991-06-24 1993-07-27 American Cyanamid Co Transplanting composition containing biologically active protein, peptide or polypeptide
JPH08500599A (en) * 1992-09-01 1996-01-23 ベーリンガー マンハイム ゲーエムベーハー Stretched splittable tablets
JPH0853345A (en) * 1994-08-10 1996-02-27 Pfizer Pharmaceut Co Ltd Divisible tablet provided with film coating
JPH08277217A (en) * 1995-04-05 1996-10-22 Sumitomo Pharmaceut Co Ltd Splittable tablet
JPH10175850A (en) * 1996-12-12 1998-06-30 Dainippon Pharmaceut Co Ltd Deformed type division tablet
JPH11152221A (en) * 1997-07-30 1999-06-08 Jenapharm Gmbh Bioadhesive tablet and its production
WO1999051207A1 (en) * 1998-04-03 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Split tablet and press-through pack
JP2002531225A (en) * 1998-12-04 2002-09-24 クノル アクチエンゲゼルシヤフト Dividable solid dosage form and method for producing the same
JP2002028222A (en) * 2000-04-28 2002-01-29 Kyowa Hakko Kogyo Co Ltd Tablet dividing appliance, tablet and press-through pack

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 1989, Vol.15, No.3, JPN6008021919, pages 343 - 359, ISSN: 0001038183 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255066A1 (en) * 2007-09-28 2010-10-07 Lintec Corporation Orally-administered agent
US20100278899A1 (en) * 2007-12-06 2010-11-04 Lintec Corporation Edible film
US20110027325A1 (en) * 2008-03-28 2011-02-03 Lintec Corporation Orally-administered agent
US20110182954A1 (en) * 2008-09-29 2011-07-28 Lintec Corporation Orally-administered agent
JP2018140973A (en) * 2017-02-28 2018-09-13 花王株式会社 Bath agent
CN109131198A (en) * 2018-10-29 2019-01-04 湖北航天化学技术研究所 A kind of gas generant for air cell tablet and its preparation process and gasifier system

Similar Documents

Publication Publication Date Title
JP5986984B2 (en) Multilayer tablet, method for producing the same, and method for suppressing delamination
JP2008501025A5 (en)
JP6022410B2 (en) Method for producing composite granulated product containing low-substituted hydroxypropylcellulose
JP5696050B2 (en) Antacid / loose tablets
JP2005145821A (en) Tablet preparation
JP5564040B2 (en) tablet
US20220401394A1 (en) Oral tablets comprising roller-compacted granules of naproxen sodium, methods of preparing thereof, and methods of using thereof
JP2009541341A (en) Segmented drug dosage form
Ozeki et al. Development of dividable one-step dry-coated tablets (Dividable-OSDRC) and their evaluation as a new platform for controlled drug release
JP5458096B2 (en) Nucleated orally disintegrating tablets
IL254159B2 (en) Tripulse release stimulant formulations
HU191138B (en) Process for producing tablets of regulated resolution of the active agents
JP7360949B2 (en) Circular orally disintegrating tablet
JP6857049B2 (en) Bathing agent
JP7385367B2 (en) Orally disintegrating tablet
JP7098008B2 (en) Laminated tablets and their manufacturing methods
JP7203726B2 (en) tablet
JP2005306770A (en) Intraoral quick collapse type preparation and method for producing the same
JPWO2020032227A1 (en) Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
AGIBA et al. PHARMACOTECHNICAL DEVELOPMENT AND OPTIMIZATION OF MULTILAYERED TABLETS: AN UPDATED INDUSTRIAL REVIEW WITH EMPHASIS ON BILAYER TABLETS
JP6548809B2 (en) Method for producing oral patch
TWI394594B (en) Pharmaceutical tablet composition and manufacturing method thereof
JP2016204296A (en) Laminated tablet, and method for producing the same
Srivastava et al. Formulation development and evaluation of atenolol fast disintegrating tablets for treatment of hypertension
Ologunagba et al. Formulation and evaluation of dispersible isoniazid tablets for paediatric use: an extemporaneous model formulary application in a resource limited setting

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090324